{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.009","upperLimit":"0.009","value":"0.009"},{"groupId":"OG002","lowerLimit":"-0.017","upperLimit":"0.003","value":"-0.007"},{"groupId":"OG003","lowerLimit":"-0.040","upperLimit":"0.002","value":"-0.015"}]}],"title":"Cycle 1 Day 29 (n=0, 1, 2, 5)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.003","upperLimit":"0.003","value":"0.003"},{"groupId":"OG002","lowerLimit":"-0.010","upperLimit":"-0.008","value":"-0.009"},{"groupId":"OG003","lowerLimit":"-0.036","upperLimit":"0.018","value":"0.001"}]}],"title":"Cycle 1 Day 57 (n=0, 1, 2, 5)"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.007","upperLimit":"0.007","value":"0.007"},{"groupId":"OG002","lowerLimit":"-0.003","upperLimit":"0.004","value":"0.001"},{"groupId":"OG003","lowerLimit":"-0.044","upperLimit":"0.017","value":"-0.005"}]}],"title":"Cycle 1 Day 85 (n=0, 1, 2, 4)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"PSA relative velocity (PSA RV) was defined as = (d\\[PSA\\]/dt)/ \\[PSA\\], where \\[PSA\\] =concentration of PSA, and t= time, and in the limit reflects the instantaneous change in PSA levels as a fraction of total PSA level. Decreases in PSA RV may occur while measured \\[PSA\\] is still rising, and may indicate that continued therapy may lead to a treatment benefit, particularly in the setting of immunotherapy, where expansion of an effective immune response is likely to require weeks to mature. Baseline PSA RV was based on the velocity of last PSA measurement before the first infusion of study drug and the screening PSA measurement.","dispersionType":"Full Range","groups":[{"description":"0.3 mg of nivolumab per kg of body weight was administered in a single IV infusion on Day 1 with 10% of the dose infused over 6 minutes and after a 1 hour observation period, the balance was administered over 60 minutes. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG000","title":"0.3 mg/kg Nivolumab"},{"description":"1 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG001","title":"1 mg/kg Nivolumab"},{"description":"3 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG002","title":"3 mg/kg Nivolumab"},{"description":"10 mg of nivolumab per kg of body weight was administered in a single IV infusion over 60 minutes on Day 1. Eligible participants could be re-treated and receive 2 more doses (1 dose every 4 weeks) at same dose as the single dose if: disease was stable, no drug intolerance was observed, no CR or PR was observed, or they had a positive immunogenicity sample within 4 weeks prior to re-treatment. Those who responded to therapy with a CR or PR were eligible for long-term follow-up until either PD or 2 years elapsed.","id":"OG003","title":"10 mg/kg Nivolumab"}],"paramType":"MEDIAN","populationDescription":"The PSA evaluable population includes all participants in the study who received complete dose(s) of nivolumab and has a baseline PSA assessment and at least 1 post-baseline PSA assessment.","reportingStatus":"POSTED","timeFrame":"Day 29, Day 57, Day 85","title":"Mean Change From Baseline in PSA Relative Velocity at Days 29, 57, and 85 With Cycle 1 in PSA Evaluable Population","type":"SECONDARY","unitOfMeasure":"percentage of total PSA level"}